IP Library Granted Patent US 11,234,965
Granted Patent B2
US 11,234,965 · App. 16/276,337 · Granted Feb 1, 2022

Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions

Inventors: Gregory A. Demopulos (Mercer Island, WA); Vincent A. Florio (Seattle, WA)
Assignee: OMEROS CORPORATION
A61K31/407A61K9/0048A61K31/137A61K31/192A61K31/405A61K31/4174
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,234,965
App. No.
16/276,337
Granted
Feb 1, 2022
Kind
B2
Abstract

The present invention provides methods for inhibiting postoperative inflammatory conditions following ophthalmologic surgical procedures by administering intraocularly during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory agent and an alpha-1 adrenergic mydriatic agent, such as a liquid irrigation solution of ketorolac and phenylephrine.

Claims (9)

1. A method for reducing the incidence or severity of postoperative cystoid macular edema following an ophthalmologic surgical procedure in a subject with an elevated risk of suffering from a postoperative cystoid macular edema, the method comprising:

administering intracamerally to the subject during an ophthalmologic surgical procedure an effective amount of a solution including a nonsteroidal anti-inflammatory drug (NSAID) and an alpha-1 adrenergic receptor agonist mydriatic agent in an intraocular irrigation carrier, wherein the effective amount is the amount of the solution is sufficient for uptake of an amount of the NSAID in ocular tissues sufficient for at least 90% inhibition of baseline cyclooxygenase-1 and cyclooxygenase-2 activity levels in ocular tissues for a period of at least eight hours postoperatively,

wherein the NSAID is ketorolac and the mydriatic agent is phenylephrine, and

wherein the subject with an elevated risk of suffering from a postoperative cystoid macular edema is over 65 years of age or has diabetes mellitus.

2. The method of claim 1 , wherein the solution comprises phenylephrine at a concentration of from 240 to 720 μM and the ketorolac is present at a concentration of from 44 to 134 μM.

3. The method of claim 1 , wherein a sufficient amount of the NSAID and the mydriatic agent are included in the solution to maintain an intraoperative pupil diameter of at least 6.0 mm during the procedure.

4. The method of claim 1 , wherein the solution is administered by continuous intracameral irrigation during the procedure.

5. The method of claim 4 , wherein the solution is administered by continuous intracameral irrigation during the procedure followed by injection of a bolus of the solution at the end of the procedure.

6. The method of claim 1 , wherein the solution is administered by intracameral injection during a procedure in which another therapeutic agent is injected intraocularly.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2024
From: RAYNER SURGICAL GROUP LIMITED
To: RAYNER INTRAOCULAR LENSES LIMITED
Reel/Frame 068708/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2024
From: MACULA BIDCO LIMITED
To: RAYNER SURGICAL GROUP LIMITED
Reel/Frame 068696/0334 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2024
From: RAYNER SURGICAL (IRELAND) LIMITED
To: MACULA BIDCO LIMITED
Reel/Frame 068182/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 7, 2023
From: RAYNER SURGICAL INC.
To: RAYNER SURGICAL (IRELAND) LIMITED
Reel/Frame 063880/0572 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S COUNTRY PREVIOUSLY RECORDED AT REEL: 059353 FRAME: 0191. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded May 19, 2022
From: OMEROS CORPORATION
To: RAYNER SURGICAL INC.
Reel/Frame 060129/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2022
From: OMEROS CORPORATION
To: RAYNER SURGICAL INC.
Reel/Frame 059353/0191 →